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Abstract A targeted delivery vehicle (DV) was developed for
intracellular transport of emerging botulinum neurotoxin
(BoNT) antagonists. The DV consisted of the isolated heavy
chain (HC) of BoNT/A coupled to a 10-kDa amino dextran via
the heterobifunctional linker 3-(2-pyridylthio)-propionyl hydra-
zide. The HC served to target BoNT-sensitive cells and promote
internalization of the complex, while the dextran served as a
platform to deliver model therapeutic molecules to the targeted
cells. To determine the ability of this chimeric glycoprotein to
enter neurons, dextran and HC were labeled independently with
the fluorescent dyes Oregon green 488 and Cy3, respectively.
Internalization of DV was monitored in primary cortical cells
using laser confocal microscopy. Incubation of cells for 24 h with
DV resulted in discrete punctate labeling of both soma and
processes. The Cy3 and Oregon green 488 signals were generally
co-localized, suggesting that the complex remained in the same
intracellular compartment during the initial 24 h. The DV-
associated fluorescence was reduced progressively by co-applica-
tion of increasing concentrations of unlabeled BoNT/A holotox-
in. The results suggest that the BoNT/A HC is able to mediate
internalization of a coupled dextran, even though the latter bears
no resemblance to the BoNT/A light chain (LC). The HC of
BoNT/A thus offers promise as a selective carrier to deliver
BoNT antagonists to the nerve terminal cytoplasm for inhibiting
the proteolytic activity of internalized BoNT/A LC. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
Key words: Botulinum neurotoxin; Targeted drug delivery;
Laser confocal microscopy; Fluorescent probe
1. Introduction
The botulinum neurotoxins (BoNTs) comprise a family of
seven distinct neurotoxic proteins (A^G) that are the most
lethal substances known to mankind [1,2]. Exposure to
BoNT results in inhibition of acetylcholine release leading to
muscle weakness, paralysis, respiratory arrest and death [3].
The toxins are dichain proteins consisting of a V100-kDa
heavy chain (HC) and a V50-kDa light chain (LC), coupled
by a single disul¢de bond and non-covalent interactions [4].
The HC is responsible for cell surface binding and internal-
ization and is devoid of toxicity when isolated from the LC
[5]. The LC is a zinc metalloprotease that cleaves one of three
intracellular proteins responsible for neurotransmitter release:
synaptobrevin, syntaxin or synaptosomal-associated protein
of 25 kDa [6]. Isolated LC also lacks toxicity due to its in-
ability to gain access to the neuronal cytosol but manifests
this property if transported intracellularly by microinjection
or liposome delivery [7].
The BoNTs are best known for their role in mediating
food-borne, wound and infant botulism [1]. Their high po-
tency and ease of production also render the BoNTs potential
biological warfare agents [8]. Although an e¡ective vaccine is
available, the relatively low incidence of botulism makes wide-
spread vaccination impractical [9]. In addition, vaccinated in-
dividuals would be precluded from the therapeutic bene¢t of
BoNT for treatment of dystonias and movement disorders
[10].
Current treatment for BoNT intoxication consists of infu-
sion of trivalent equine antitoxin to neutralize circulating tox-
in and supportive care [2]. The former approach is limited by
a brief therapeutic window, since much of the toxin is inter-
nalized by the time symptoms appear [11]. A post-exposure
pharmacological treatment for botulism has been pursued for
over a decade but has met with only limited success. Di⁄cul-
ties with current drug candidates include low e⁄cacy [12],
high systemic toxicity [13,14] and poor bioavailability [15].
Consequently, there is a compelling need for the development
of e¡ective BoNT inhibitors and for devising strategies to
direct inhibitors into the nerve terminal cytosol. The problems
of low e⁄cacy are being addressed by new synthetic ap-
proaches [16,17], but speci¢c targeting of drugs will be needed
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for selective intracellular delivery of su⁄ciently high concen-
trations to inhibit the proteolytic activity of the LC.
The current study describes the design of a delivery vehicle
(DV) for the selective intracellular targeting of BoNT antag-
onists. The DV consists of a chimeric glycoprotein in which a
10-kDa amino dextran is covalently attached through a bi-
functional linker to the BoNT/A HC. The HC serves to target
cells containing BoNT/A surface receptors and to promote
internalization of the complex; the dextran serves as an inert
carrier of BoNT/A antagonists. To visualize cellular uptake,
DV was di¡erentially labeled with the £uorescent dyes Cy3
(Amersham Biosciences, Piscataway, NJ, USA) and Oregon
green 488 (2P,7P-di£uoro£uorescein, Molecular Probes, Eu-
gene, OR, USA), and evaluated in cultured cortical cells.
The results indicate that the DV was able to undergo neuronal
uptake and that this process was inhibited by the presence of
unlabeled BoNT/A holotoxin in a concentration-dependent
fashion. The success of the DV prototype suggests that the
approach of using a targeted delivery system for botulinum
antagonists is feasible.
2. Materials and methods
2.1. Strategy for DV design
A schematic representation of the DV used in the present study is
illustrated in Fig. 1. The following steps were involved in the synthesis
of this chimeric glycoprotein: (1) labeling of pure BoNT/A holotoxin
with the £uorescent dye Cy3, (2) isolation and puri¢cation of the Cy3-
labeled HC, (3) oxidation of the hydroxyl groups in the dextran to
allow attachment of the linker 3-(2-pyridylthio)-propionyl hydrazide
(PDPH, Pierce Biochemical, Rockford, IL, USA), (4) labeling of the
dextran with Oregon green 488, and (5) coupling of the labeled dex-
tran and HC. Coupling required disul¢de exchange of one of four
sulfhydryls of the HC with the functional group of the linker to
constitute the complete DV. The detailed synthetic procedures are
provided below.
2.2. BoNT/A production and puri¢cation
BoNT/A was obtained from the Hall strain of Clostridium botuli-
num. Cultures were grown statically in 10-l volumes of toxin produc-
tion medium consisting of 2.0% NZ TT casein hydrolysate (She⁄eld
Laboratories, Norwich, NY, USA), 1.0% yeast extract (Difco Labo-
ratories, Detroit, MI, USA) and 0.5% dextrose, pH 7.3^7.4. The cul-
tures were incubated for 4 days at 37‡C. BoNT/A was isolated and
puri¢ed according to the methods of Goodnough and Johnson [18].
2.3. Cy3 labeling of BoNT/A and chain separation
Fluorescent labeling of isolated HC was not attempted since pre-
liminary experiments indicated that this approach resulted in extensive
degradation of the HC. Instead, labeling with Cy3 was performed
prior to chain separation. Pure BoNT/A in 20 mM sodium borate,
40 mM sodium phosphate (pH 8.4) was labeled with the monoreactive
succinimidyl ester of the £uorescent cyanine dye Cy3 using 25 Wg dye
per mg neurotoxin. The reaction of BoNT/A and Cy3 was carried out
overnight at room temperature in the dark. Cy3 reacted with free
amines in the toxin and was predominantly associated with the O-
amino groups of lysine residues. Unreacted dye was removed by over-
night dialysis at 4‡C against 10 vol of 20 mM sodium borate and 40
mM sodium phosphate (pH 8.4) with three bu¡er changes. Addition
of Cy3 resulted in a small reduction in speci¢c toxicity of BoNT/A
from 1.05U108 to 7.5U107 mouse i.p. LD50/mg.
BoNT/A was separated into HC and LC according to the method
of Sathyamoorthy and DasGupta [4]. HC puri¢cation was determined
to be s 99% complete by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) (Fig. 2). Puri¢ed Cy3-labeled HC was
stored as an ammonium sulfate precipitate (39 g solid ammonium
sulfate per 100 ml) at 4‡C until required for coupling with dextran.
The speci¢c toxicity of the puri¢ed HC preparations was 9500 mouse
i.p. LD50/mg protein due to contamination by trace quantities of
residual holotoxin.
2.4. Dextran preparation
Amine-reactive dextran (Molecular Probes, Eugene, OR, USA) was
prepared for conjugation with BoNT/A HC by reaction with sodium
periodate followed by addition of the heterobifunctional linker
PDPH. Dextran (10 kDa, 15 mg/ml) was ¢rst modi¢ed by oxidation
of hydroxyls using sodium periodate (10 mM ¢nal concentration in
100 mM sodium acetate, pH 5.5, for 20 min at 22‡C in the dark).
Oxidation of vicinal hydroxyl groups to the corresponding aldehydes
is required for reaction with the hydrazide portion of the linker. Ex-
cess periodate was removed by size-exclusion chromatography (SEC)
on Sephadex G25 columns (1 cmU10 cm) equilibrated with 100 mM
sodium acetate, pH 5.5. Immediately upon elution, the oxidized dex-
tran was reacted with 5 mM PDPH and maintained overnight at 22‡C
in the dark. Unreacted PDPH was removed by SEC in a phosphate-
bu¡ered saline (PBS) consisting of 20 mM sodium phosphate (pH 7.4)
and 150 mM NaCl. The concentration of incorporated PDPH was
determined by reduction of eluted dextran with 5 mM dithiothreitol
and measuring the increase in absorbance at 343 nm. Modi¢ed dex-
tran (13 mg) was reacted with the succinimidyl ester of Oregon green
488 (5 mg) (Molecular Probes) in 3.0 ml of PBS at 22‡C overnight in
the dark. Unreacted Oregon green 488 was removed by SEC on Seph-
adex G25 columns equilibrated with PBS plus 1 mM ethylenediami-
netetraacetic acid (EDTA) at pH 7.4.
2.5. Conjugation of HC and dextran
Puri¢ed HC (ammonium sulfate precipitate) was collected by cen-
trifugation (10 000Ug, 15 min at 4‡C) and dissolved in ice-cold PBS,
2 M urea and 10 mM dithiothreitol. Dithiothreitol and urea were
removed from HC preparations by SEC on columns equilibrated
with PBS, plus 1 mM EDTA and 1 mM phenylmethylsulfonyl £uoride
(Sigma-Aldrich, St. Louis, MO, USA). Fractions containing HC were
immediately reacted with labeled dextran. Conjugation was monitored
by measuring increases in absorbance at 343 nm. This procedure en-
tails formation of a disul¢de linkage between a sulfhydryl group on
one of the four reactive cysteine residues of the HC and the sulfur of
the PDPH linker associated with the dextran. Reactions were stopped
at various time points by addition of methionine to a ¢nal concen-
tration of 2 mM to determine optimal coupling times.
2.6. Stoichiometry of dye and linker incorporation
The degree of Cy3 incorporation into HC was estimated spectro-
photometrically using an extinction coe⁄cient of 1.5U105 M31 cm31
at 552 nm for the dye and 1.4U105 M31 cm31 at 278 nm for the HC.
A correction of 8% for absorbance of Cy3 at 278 nm was used when
determining HC concentration. Fluorescent label density on dextrans
was calculated using 8.4U104 M31 cm31 as the extinction coe⁄cient
of the Oregon green 488 at 494 nm; PDPH linker density was deter-
mined using an extinction coe⁄cient of 8.08U103 M31 cm31 at 343
nm following reduction with 5 mM dithiothreitol.
2.7. Gel electrophoresis
Protein samples were separated electrophoretically using the Phar-
macia Phastsystem (Amersham Biosciences, Piscataway, NJ, USA)
according to the manufacturer’s instructions. Precast 10^15% acryl-
amide gels were stained with 0.1% Coomassie brilliant blue R250 in
16.7% acetic acid/41.7% methanol. Gels were destained in 7.5% acetic
acid/25% methanol. Samples for electrophoresis were solubilized in 50
mM Tris^HCl, 5 M urea, 5% SDS, 20% glycerol, pH 6.8. Where
indicated, samples were reduced by addition of dithiothreitol at a ¢nal
concentration of 0.5%. All samples for SDS^PAGE were boiled for
5 min prior to electrophoresis.
2.8. Cell culture
Cultures of dissociated mouse cortical cells were prepared as de-
scribed by Matthews et al. [19]. Primary mouse cortical cells were
obtained from CD-1 mice on embryonic day 18. Tissues were isolated
and placed at 37‡C in a dissociation medium consisting of Ca2- and
Mg2-free Hanks’ balanced salt solution containing 1 mM sodium
pyruvate, 10 mM N-[2-hydroxyethyl]piperazine-NP-2-ethanesulfonic
acid (pH 7.3) and 0.025% trypsin. After 10 min, trypsin was diluted
by addition of nine volumes of dissociation medium. Cells were tri-
turated and passed through a 30-Wm mesh to remove large aggregates.
The suspension was centrifuged at 1500Ug for 2 min, and the pellet
was resuspended in growth medium (Neurobasal medium, 2% B27,
0.5 mM L-alanyl-L-glutamine, 100 U/ml penicillin, 100 Wg/ml strepto-
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mycin, 0.25 Wg/ml amphotericin; Life Technologies) with 1% horse
serum. Cells were plated on poly-D-lysine-coated Thermanox plastic
coverslips (Nunc, Naperville, IL, USA) in 24-well plates at a density
of 105 cells/cm2. Cells were maintained in a humidi¢ed incubator at
37‡C in an atmosphere of 5% CO2/10% O2/85% air and used 7^9 days
after plating.
2.9. Uptake of DV by cortical cells and £uorescent imaging
Cells were exposed to DV, Cy3-labeled HC, or Oregon green 488-
labeled dextran in growth medium for 24 h at a concentration of 200
nM at 37‡C. Cells were subsequently washed three times with control
growth medium and ¢xed overnight with 2% paraformaldehyde. Plas-
tic coverslips containing ¢xed cells were mounted between a glass slide
and glass coverslip and viewed on a Zeiss LSM laser confocal micro-
scope. Oregon green 488 was excited at 488 nm and observed through
a 515-nm cuto¡ ¢lter. Cy3 was excited at 543 nm and detected with a
565-nm cuto¡ ¢lter. To minimize photobleaching, Slowfade Light
(Molecular Probes) 1:50 was added to the mounting medium. Images
were collected with Zeiss LSM software.
3. Results
3.1. Incorporation of dyes and linker
On average, 2.3 mol of Oregon green 488 and 3.2 mol of
linker were bound to each mol of dextran; 2.8 mol Cy3 was
attached to each mol of HC. The coupling between HC and
dextran was rapid and appeared to be complete within 5 min.
This is demonstrated by SDS^PAGE in Fig. 3. Lanes 1 and
3 represent DV formed after conjugating dextran and HC for
5 and 75 min, respectively. In each case, the DV is unresolved
due to variations in the molecular weights of the conjugated
10-kDa dextran. However, even at 5 min, there is no evidence
of free unconjugated HC, indicating that the reaction had
proceeded to completion. The incorporated HC is revealed
after DV is exposed to 50 mM dithiothreitol, which reduces
the disul¢de that couples the dextran to the HC (lanes 2 and
4). A disul¢de bond also couples the LC to HC in BoNT
holotoxin (lanes 5 and 6).
3.2. Uptake of DV by cortical cells
Cortical cells exposed to 200 nM DV for 24 h showed
prominent Cy3 and Oregon green 488 £uorescence as illus-
trated in Fig. 4A1^A3. The staining pattern of each dye was
punctate and perinuclear. The punctate nature of the staining
suggests clustering of DV in vesicles. Exclusion of nuclear
staining indicates that the DV is intracellular, as expected
for material transported by BoNT HC. Staining of soma
and processes was of approximately equal intensity. This
may re£ect a similarity of transport sites or subsequent redis-
tribution of DV after internalization.
The Cy3 and Oregon green staining patterns exhibited a
marked degree of co-localization, which is especially apparent
in the two-color overlay (Fig. 4, A3). The high level of co-
incidence suggests that the HC and dextran are still coupled at
this stage, or that the components are con¢ned to the same
intracellular compartment.
To determine whether the presence of dextran impedes the
Fig. 1. Schematic representation of the DV for transport of BoNT/A antagonists. The PDPH linker is bound to one of four possible cysteine
(C) sulfhydryl groups on the BoNT/A HC. It is shown attached to C454, which normally participates in the disul¢de linkage with the LC. Cy3
and Oregon green 488 are bound to O-amino groups of lysine in the HC and dextran, respectively. The dextran is conjugated to the HC by a
C^N bond in one of the glucose residues. On average, each mol of HC contained 2.8 mol of Cy3; each mol of dextran contained 2.3 mol of
Oregon green 488 and 3.2 mol of PDPH.
Fig. 2. SDS^PAGE analysis of BoNT/A and isolated chains. Lane
1: BoNT/A holotoxin; lane 2: BoNT/A holotoxin reduced with 50
mM dithiothreitol showing component HC (V100 kDa) and LC
(V50 kDa); lane 3: puri¢ed BoNT/A LC; lane 4: puri¢ed BoNT/A
HC. HC preparations were determined to be s 99% pure.
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translocation of the HC, experiments were also performed on
Cy3-labeled HC lacking the dextran moiety. Comparison of
the Cy3 £uorescence of the complete DV with that of dextran-
free HC revealed a similar £uorescence pattern and intensity
(Fig. 4A2,B2). Thus the dextran does not appear to interfere
with the internalization of the HC.
To demonstrate that the £uorescent signal represents spe-
ci¢c intracellular transport by BoNT/A HC, cortical cells were
exposed to Oregon green 488-labeled dextran under condi-
tions identical to those used for monitoring internalization
of DV. As is evident from Fig. 4C1^C3, there was no detect-
able Oregon green 488 £uorescence when cells were incubated
with labeled dextran alone.
3.3. Competition between DV and BoNT/A
The data in Fig. 4 suggest that internalization of the DV
requires the presence of the BoNT/A HC. However, it is not
clear whether tra⁄cking of DV is comparable to that of the
BoNT/A holotoxin. A similarity of the internalization mech-
anism may be inferred by demonstrating that BoNT/A holo-
toxin can compete with DV. Fig. 5 shows the results of com-
petition experiments in which cortical cultures were exposed
to DV alone (A1 and B1) or to DV plus a 2-, 5-, or 10-fold
molar excess of BoNT/A holotoxin. In this experiment, the
Cy3 label was omitted to avoid possible alteration of the HC,
and only the Oregon green 488 dextran label was present. As
is clear from Fig. 5, there was a pronounced concentration-
dependent reduction in the £uorescence intensity of the DV in
the presence of BoNT/A holotoxin. When BoNT/A was ap-
plied at 10-fold excess (A4 and B4), the Oregon green 488
signal was no longer visible. These results suggest that DV
gains entry into cortical cells by the same route as that used
by BoNT/A holotoxin.
4. Discussion
The present study represents one of the ¢rst attempts to
develop a targeted drug delivery system for treatment of
BoNT intoxication. The need for such a system has long
been recognized due to di⁄culties involved in directing
therapeutic agents to cholinergic nerve terminals. The ¢rst
report suggesting the feasibility of targeted delivery for
BoNT was provided by Zhou et al. [20]. These authors
showed that a catalytically inactive BoNT was able to trans-
port the LC of tetanus toxin into cells. The current study
has extended this concept by demonstrating that the HC
is capable of transporting a branched polysaccharide with
multiple drug binding sites into the neuronal interior (Fig. 4).
For drug delivery, antagonist of BoNT LC would be attached
to sites currently occupied by the Oregon green 488 reporter
dye (Fig. 1).
This study also demonstrated that internalization of DV is
reduced by the presence of BoNT/A, suggesting that the initial
tra⁄cking of DV is similar to that of BoNT/A holotoxin (Fig.
5). It is not clear, however, whether competition between DV
and holotoxin occurs at the level of receptor binding or is
exerted at subsequent steps in the internalization of the DV
complex.
The targeted DV had two distinct components: the pure
HC of BoNT/A and an inert dextran polymer (Fig. 1). The
HC ensures that the DV will interact with cells that possess
external receptors for BoNT, thus minimizing systemic toxic-
ity of emerging BoNT antagonists [21]. The HC also promotes
internalization of the attached cargo, making the BoNT an-
tagonists available for inhibition of internalized LC. Although
cortical cells are not generally involved in botulinum intoxi-
cation, they have been shown to be susceptible to BoNT as
determined by £uorescent probes as well as by substrate cleav-
age studies [22,23].
The role of the dextran is to provide a delivery platform for
reversible binding and dissociation of BoNT inhibitors. Dex-
trans were selected for this function because they are inert,
non-toxic and stable [24]. Dextrans are hydrophilic polysac-
charides characterized by their moderate to high molecular
weight, good aqueous solubility and low toxicity. They are
widely used as both anterograde and retrograde tracers in
neurons and for numerous other applications [24]. Their un-
common poly-(D-1,6-glucose) linkage renders them resistant
to cleavage by most endogenous cellular glycosidases. They
also have low immunogenicity.
The 10-kDa dextran represents the ¢rst attempt at ¢nding a
suitable carrier for BoNT inhibitors. While dextrans possess a
number of advantages as drug carriers, they also have an
obvious limitation; dextrans contain only a small number of
drug binding sites. For the 10-kDa dextran used in the current
study, if drugs are coupled to the amino groups, a maximum
of 3.7 mol of inhibitor can be attached for each mol of DV.
Since the best BoNT antagonists currently available have Ki
values in the micromolar range, it is unlikely that delivery of
such a small quantity of therapeutic agents will be e¡ective in
inhibiting the proteolytic activity of the LC [15^17]. Dextrans
of higher molecular weight may overcome this di⁄culty but at
the cost of diminished targeting speci¢city. In preliminary
studies, we examined the ability of DVs coupled to a 40-
kDa amino dextran (6.1 drug binding sites per mol) to enter
cultured cortical and spinal cord cells. Although the DV was
able to enter both cell types, the larger dextran underwent
signi¢cant internalization in the absence of HC. Other poten-
tial carriers include polyethylene glycol and polylysine, and
Fig. 3. SDS^PAGE analysis of DV and BoNT/A on 10^15% Phast-
gel stained with 0.1% Coomassie brilliant blue R250. Odd-numbered
lanes correspond to unreduced DV (lanes 1 and 3) or unreduced
BoNT/A holotoxin (lane 5); even-numbered lanes correspond to re-
duced DV (lanes 2 and 4) or reduced BoNT/A with V100-kDa HC
and V50-kDa LC (lane 6). Reduction was performed by addition
of 50 mM dithiothreitol prior to electrophoresis. HC and dextran
were conjugated for 5 min in lanes 1 and 2 and for 75 min in lanes
3 and 4. Lanes 5 and 6 show BoNT/A in the absence and presence
of 50 mM dithiothreitol. The complete DV is not resolved in lanes
1 and 3 due to variations in molecular weight of the 10-kDa dex-
tran. The lack of a distinct HC band in lanes 1 and 3 indicates that
coupling of HC and dextran was complete at both time points.
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Fig. 5. Fluorescent micrographs of cortical cells demonstrating that BoNT/A holotoxin competes with DV for entry into cells. Images in rows
A and B were obtained from duplicate cultures exposed for 24 h under the following conditions: (1) DV (200 nM) in the absence of BoNT/A;
(2) DV (200 nM) and BoNT/A (400 nM); (3) DV (200 nM) and BoNT/A (1 WM); and (4) DV (200 nM) and BoNT/A (2 WM). DV and
BoNT/A were added simultaneously. To avoid potential complications from possible Cy3-mediated alterations of HC, the latter was omitted
and only Oregon green 488 was used. Note the progressive reduction in £uorescence with increasing concentrations of BoNT/A. Micrographs
were obtained on a Zeiss LSM laser confocal microscope using a 63U oil immersion objective.
Fig. 4. Fluorescent images of cultured cortical cells. Cells were incubated for 24 h with 200 nM solutions of £uorescently labeled DV (A1^A3),
HC (B1^B3) or dextran (C1^C3). Dextran, HC and DV were labeled with Oregon green 488, Cy3 or both £uorophores, respectively. The mi-
crographs in column 1 show £uorescence elicited at an excitation wavelength of 488 nm (green); the images in column 2 were elicited at 543
nm (red). Column 3 represents overlays of the two images. Micrographs were obtained on a Zeiss LSM laser confocal microscope using a 63U
oil immersion objective.
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these will be evaluated in subsequent studies for their ability
to carry a larger cargo while retaining speci¢city of targeting.
According to our current understanding of BoNT tra⁄ck-
ing, the neurotoxin ¢rst binds to surface receptors and is then
internalized via receptor-mediated endocytosis [1]. Initially,
the toxin is con¢ned to endocytotic vesicles; acidi¢cation of
these vesicles leads to a conformational change in the toxin.
The N-terminal domain of the HC then forms channels in the
endocytotic vesicle membrane allowing release of the LC into
the cytosol [1]. The punctate nature of the staining for DV
and co-localization of the dextran and HC suggest that both
components of the DV may still be located in endocytotic
vesicles 24 h after incubation (Fig. 4). This ¢nding raises the
possibility that the dextran is unable to use the same pathway
as the LC to escape from endocytotic vesicles. Even if the
dextran remains membrane-bound, BoNT inhibitors could
still be delivered to the cytosol if the drugs are membrane-
permeable and are able to dissociate from the dextran under
the mild acidic conditions that occur in these cellular com-
partments.
5. Conclusions
The present study examined the feasibility of an HC-based
DV for intracellular transport of BoNT antagonists. The re-
sults indicate that the DV was capable of neuronal targeting
and that entry into cells occurred by mechanisms common to
BoNT holotoxin. Future e¡orts will focus on testing poly-
meric carriers with higher ligand binding capacity to allow
evaluation of DV constructs coupled to actual BoNT inhib-
itors. Although cellular targeting strategies have not always
been successful, the selectivity of BoNT HC o¡ers cause for
optimism.
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